Billings LK, Hsia S, Bays H, Tidemann-Miller B, et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2025 Nov 6:S0140-6736(25)02155-5. doi: 10.1016/S0140-6736(25)02155.
PMID: 41207310